Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Request a free trial

No credit card. No commitment.

Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Profile for Tradename: GLUCOPHAGE

« Back to Dashboard
Glucophage is a drug marketed by Bristol Myers Squibb and is included in two NDAs. It is available from two suppliers. There are two patents protecting this drug.

The generic ingredient in GLUCOPHAGE is metformin hydrochloride. There are forty-six drug master file entries for this compound. Eight suppliers are listed for this compound. There are two tentative approvals for this compound. Additional details are available on the metformin hydrochloride profile page.

Summary for Tradename: GLUCOPHAGE

Patents:2
Applicants:1
NDAs:2
Suppliers / Packagers: see list5

Pharmacology for Tradename: GLUCOPHAGE

Ingredient-typeBiguanides
Drug ClassBiguanide

Clinical Trials for: GLUCOPHAGE

Evaluate Adherence to Treatment With Glucophage Sachets Versus Tablets in Diabetes Type 2 Patients Previously Treated With Metformin Tablets
Status: Withdrawn Condition: Diabetes Mellitus Type 2

Bioequivalence Study of 2.5-mg Saxagliptin and 500-mg Glucophage in Tablets and a Fixed-dose Combination Tablet in Healthy Participants
Status: Completed Condition: Type 2 Diabetes Mellitus

Bioequivalence Study of Fixed Dose Combination of 2.5 mg Saxagliptin/850 mg Metformin Tablet Relative to 2.5 mg Onglyza and 850 mg Glucophage Tablets Co-Administered
Status: Completed Condition: Type 2 Diabetes Mellitus

A Study to Evaluate the Effect of Multiple Doses of Isavuconazole on the Pharmacokinetics of Metformin
Status: Completed Condition: Pharmacokinetics of Isavuconazole; Pharmacokinetics of Metformin; Healthy Subjects

A Study Comparing the Amount of Metformin and After Taking a Combination Tablet vs. Separate Tablets
Status: Completed Condition: Healthy Volunteers

Bioequivalence Study of 500 mg and 1000 mg Glucophage (Metformin) Tablets in Healthy Subjects
Status: Completed Condition: Type 2 Diabetes Mellitus

Bioequivalence Study of Saxagliptin and Glucophage Combination Formulations in Healthy Subjects (B)
Status: Completed Condition: Type 2 Diabetes Mellitus

Crossover Study to Evaluate the Comparative Bioavailability of Two Fixed Dose Combination Tablet Formulations of Extended Release Metformin and Extended Release Glimepiride in Health Volunteers
Status: Terminated Condition: Diabetes Mellitus, Type 2

Drug-Drug Interaction Study With Metformin and Nizatidine
Status: Completed Condition: Healthy

Metformin And Chloroquine in IDH1/2-mutated Solid Tumors
Status: Not yet recruiting Condition: Glioma; Cholangiocarcinoma; Chondrosarcoma

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb
GLUCOPHAGE
metformin hydrochloride
TABLET;ORAL020357-005Nov 5, 1998RXYes<disabled><disabled>
Bristol Myers Squibb
GLUCOPHAGE XR
metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL021202-001Oct 13, 2000RXNo6,475,521<disabled><disabled>
Bristol Myers Squibb
GLUCOPHAGE
metformin hydrochloride
TABLET;ORAL020357-004Nov 5, 1998DISCNNo<disabled><disabled>
Bristol Myers Squibb
GLUCOPHAGE XR
metformin hydrochloride
TABLET, EXTENDED RELEASE;ORAL021202-004Apr 11, 2003RXYes6,660,300<disabled><disabled>
Bristol Myers Squibb
GLUCOPHAGE
metformin hydrochloride
TABLET;ORAL020357-001Mar 3, 1995RXNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc